|
1
|
Rubin BP, Heinrich MC and Corless CL:
Gastrointestinal stromal tumor. Lancet. 369:1731–1741. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giuliano K, Ejaz A, Reames BN, Choi W,
Sham J, Gage M, Johnston FM and Ahuja N: Comparing the long-term
outcomes among patients with stomach and small intestine
gastrointestinal stromal tumors: An analysis of the National Cancer
Database. J Surg Oncol. 118:486–492. 2018.PubMed/NCBI
|
|
3
|
Corless CL, Fletcher JA and Heinrich MC:
Biology of gastrointestinal stromal tumors. J Clin Oncol.
22:3813–3825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fletcher CD, Berman JJ, Corless C,
Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti
H, Rubin BP, et al: Diagnosis of gastrointestinal stromal tumors: A
consensus approach. Hum Pathol. 33:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: Pathology and prognosis at different sites. Semin
Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamamoto H and Oda Y: Gastrointestinal
stromal tumor: Recent advances in pathology and genetics. Pathol
Int. 65:9–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Benson SC, Pershadsingh HA, Ho CI,
Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA and
Kurtz TW: Identification of telmisartan as a unique angiotensin II
receptor antagonist with selective PPAR-modulating activity.
Hypertension. 43:993–1002. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kinoshita J, Fushida S, Harada S, Yagi Y,
Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Yashiro M,
et al: Local angiotensin II-generation in human gastric cancer:
Correlation with tumor progression through the activation of
ERK1/2, NF-κB and survivin. Int J Oncol. 34:1573–1582. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okamoto K, Tajima H, Ohta T, Nakanuma S,
Hayashi H, Nakagawara H, Onishi I, Takamura H, Ninomiya I, Kitagawa
H, et al: Angiotensin II induces tumor progression and fibrosis in
intrahepatic cholangiocarcinoma through an interaction with hepatic
stellate cells. Int J Oncol. 37:1251–1259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Du N, Feng J, Hu LJ, Sun X, Sun HB, Zhao
Y, Yang YP and Ren H: Angiotensin II receptor type 1 blockers
suppress the cell proliferation effects of angiotensin II in breast
cancer cells by inhibiting AT1R signaling. Oncology Rep.
27:18932012.
|
|
11
|
Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang
Y, Sun L, Sui G, Cai L and Dong X: Angiotensin II type 1 receptor
antagonists inhibit cell proliferation and angiogenesis in breast
cancer. Cancer Lett. 328:318–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koyama N, Nishida Y, Ishii T, Yoshida T,
Furukawa Y and Narahara H: Telmisartan induces growth inhibition,
DNA double-strand breaks and apoptosis in human endometrial cancer
cells. PLoS One. 9:e930502014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okazaki M, Fushida S, Harada S, Tsukada T,
Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T and Ohta T:
The angiotensin II type 1 receptor blocker candesartan suppresses
proliferation and fibrosis in gastric cancer. Cancer Lett.
355:46–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhaskaran K, Douglas I, Evans S, van Staa
T and Smeeth L: Angiotensin receptor blockers and risk of cancer:
Cohort study among people receiving antihypertensive drugs in UK
general practice research database. BMJ. 344:e26972012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Makar GA, Holmes JH and Yang YX:
Angiotensin-converting enzyme inhibitor therapy and colorectal
cancer risk. J Natl Cancer Inst. 106:djt3742014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Funao K, Matsuyama M, Kawahito Y, Sano H,
Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan is
a potent target for prevention and treatment in human prostate
cancer. Oncol Rep. 20:295–300. 2008.PubMed/NCBI
|
|
17
|
Funao K, Matsuyama M, Kawahito Y, Sano H,
Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan as
a peroxisome proliferator-activated receptor-gamma ligand is a new
target in the treatment of human renal cell carcinoma. Mol Med Rep.
2:193–198. 2009.PubMed/NCBI
|
|
18
|
Lee L, Mafura B, Lauscher J, Seeliger H,
Kreis M and Gröne J: Antiproliferative and apoptotic effects of
telmisartan in human colon cancer cells. Oncol Lett. 8:2681–2866.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rehman G, Shehzad A, Khan AL and Hamayun
M: Role of AMP-activated protein kinase in cancer therapy. Arch
Pharm (Weinheim). 347:457–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dann SG and Thomas G: The amino acid
sensitive TOR pathway from yeast to mammals. FEBS Lett.
580:2821–2829. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fingar DC and Blenis J: Target of
rapamycin (TOR): An integrator of nutrient and growth factor
signals and coordinator of cell growth and cell cycle progression.
Oncogene. 23:3151–3171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fujihara S, Asahiro M, Ogawa K, Tadokoro
T, Chiyo T, Kato K, Kobara H, Mori H, Iwama H and Masaki T: The
angiotensin II type 1 receptor antagonist telmisartan inhibits cell
proliferation and tumor growth of esophageal adenocarcinoma via the
AMPKα/mTOR pathway in vitro and in vivo. Oncotarget. 8:8536–8549.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oura K, Tadokoro T, Fujihara S, Morishita
A, Chiyo T, Samukawa E, Yamana Y, Fujita K, Sakamoto T, Nomura T,
et al: Telmisartan inhibits hepatocellular carcinoma cell
proliferation in vitro by inducing cell cycle arrest. Oncol Rep.
38:2825–2835. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang LH and He XH: Macro-management of
microRNAs in cell cycle progression of tumor cells and its
implications in anti-cancer therapy. Acta Pharmacol Sin.
32:1311–1320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J Roy Stat Soc. 57:289–300. 1995.
|
|
28
|
de Araújo Júnior RF, Leitão Oliveira AL,
de Melo Silveira RF, de Oliveira Rocha HA, de França Cavalcanti P
and de Araújo AA: Telmisartan induces apoptosis and regulates Bcl-2
in human renal cancer cells. Exp Biol Med (Maywood). 240:34–44.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sipahi I, Debanne SM, Rowland DY, Simon DI
and Fang JC: Angiotensin-receptor blockade and risk of cancer:
Meta-analysis of randomised controlled trials. Lancet Oncol.
11:627–636. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shen J, Huang YM, Wang M, Hong XZ, Song
XN, Zou X, Pan YH, Ling W, Zhu MH, Zhang XX, et al:
Renin-angiotensin system blockade for the risk of cancer and death.
J Renin Angiotensin Aldosterone Syst. 17(pii):
14703203166566792016.PubMed/NCBI
|
|
31
|
Masaki T, Shiratori Y, Rengifo W, Igarashi
K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H,
Watanabe S, et al: Cyclins and cyclin-dependent kinases:
Comparative study of hepatocellular carcinoma versus cirrhosis.
Hepatology. 37:534–543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Itami A, Shimada Y, Watanabe G and Imamura
M: Prognostic value of p27Kip1 and cyclin D1 expression
in esophageal cancer. Oncology. 57:311–317. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fukuchi M, Fukai Y, Kimura H, Sohda M,
Miyazaki T, Nakajima M, Masuda N, Tsukada K, Kato H and Kuwano H:
Prolyl isomerase Pin1 expression predicts prognosis in patients
with esophageal squamous cell carcinoma and correlates with
cyclinD1 expression. Int J Oncol. 29:329–334. 2006.PubMed/NCBI
|
|
35
|
Samples J, Willis M and Klauber-DeMore N:
Targeting angiogenesis and the tumor microenvironment. Surg Oncol
Clin N Am. 22:629–639. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Masaki T: MicroRNA and hepatocellular
carcinoma. Hepatol Res. 39:751–752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morishita A and Masaki T: miRNA in
hepatocellular carcinoma. Hepatology Res. 45:128–141. 2015.
View Article : Google Scholar
|
|
38
|
Zhou Y, Wang M, Wu J, Jie Z, Chang S and
Shuang T: The clinicopathological significance of miR-1307 in
chemotherapy resistant epithelial ovarian cancer. J Ovarian Res.
8:232015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qiu X and Dou Y: miR-1307 promotes the
proliferation of prostate cancer by targeting FOXO3A. Biomed
Pharmacother. 88:430–435. 2017. View Article : Google Scholar : PubMed/NCBI
|
